{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:19:12Z","timestamp":1768321152392,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40262-019-00832-7","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T02:02:41Z","timestamp":1574301761000},"page":"605-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-2543","authenticated-orcid":false,"given":"Alexander","family":"Solms","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-8766","authenticated-orcid":false,"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-2571","authenticated-orcid":false,"given":"Maurice J.","family":"Ahsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-3115","authenticated-orcid":false,"given":"Anita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-7195","authenticated-orcid":false,"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Garmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"1","key":"832_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1\u201347.","journal-title":"Haemophilia"},{"key":"832_CR2","doi-asserted-by":"crossref","unstructured":"Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;(9):CD003429.","DOI":"10.1002\/14651858.CD003429.pub4"},{"issue":"suppl 1","key":"832_CR3","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/pbc.24339","volume":"60","author":"C Barnes","year":"2013","unstructured":"Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer. 2013;60(suppl 1):S27\u20139.","journal-title":"Pediatr Blood Cancer."},{"issue":"8","key":"832_CR4","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1055\/s-0035-1552563","volume":"41","author":"MD Carcao","year":"2015","unstructured":"Carcao MD, Iorio A. Individualizing factor replacement therapy in severe hemophilia. Semin Thromb Hemost. 2015;41(8):864\u201371.","journal-title":"Semin Thromb Hemost."},{"issue":"4","key":"832_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/hae.13192","volume":"23","author":"D Garmann","year":"2017","unstructured":"Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned\u2014importance of including samples with factor VIII levels below the quantitation limit. Haemophilia. 2017;23(4):528\u201337.","journal-title":"Haemophilia."},{"issue":"12","key":"832_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jth.13867","volume":"15","author":"A Iorio","year":"2017","unstructured":"Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15(12):2461\u20135.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"832_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/rth2.12106","volume":"2","author":"A Iorio","year":"2018","unstructured":"Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, et al. Performing and interpreting individual pharmacokinetic profiles in patients with hemophilia A or B: rationale and general considerations. Res Pract Thromb Haemost. 2018;2(3):535\u201348.","journal-title":"Res Pract Thromb Haemost."},{"issue":"4","key":"832_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/jth.12506","volume":"12","author":"TE Coyle","year":"2014","unstructured":"Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12(4):488\u201396.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"832_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.13597","volume":"15","author":"MT Reding","year":"2017","unstructured":"Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. J Thromb Haemost. 2017;15(3):411\u20139.","journal-title":"J Thromb Haemost."},{"key":"832_CR10","unstructured":"Santagostino E, Saxena K, Kenet G, Fischer K, Biss T, Radke S, et al. PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A [abstract]. WFH World Congress 2016; 24\u201328 Jul 2016; Orlando."},{"key":"832_CR11","unstructured":"US FDA. Jivi\u00ae prescribing information. 2018. https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Package-Insert-JIVI.pdf. Accessed 01 Nov 2019."},{"issue":"4","key":"832_CR12","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1208\/ps040427","volume":"4","author":"U Wahlby","year":"2002","unstructured":"Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4(4):E27.","journal-title":"AAPS PharmSci."},{"issue":"2","key":"832_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J."},{"issue":"4","key":"832_CR14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","volume":"16","author":"S Bj\u00f6rkman","year":"2010","unstructured":"Bj\u00f6rkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010;16(4):597\u2013605.","journal-title":"Haemophilia."},{"key":"832_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-019-09634-7","author":"A McEneny-King","year":"2019","unstructured":"McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. J Pharmacokinet Pharmacodyn. 2019. https:\/\/doi.org\/10.1007\/s10928-019-09634-7(Epub 2019 May 18).","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"832_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/17425255.2016.1214711","volume":"12","author":"A McEneny-King","year":"2016","unstructured":"McEneny-King A, Iorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol. 2016;12(11):1313\u201321.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/j.1538-7836.2012.04905.x","volume":"10","author":"IM Appel","year":"2012","unstructured":"Appel IM, Grimminck B, Geerts J, Stigter R, Cnossen MH, Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost. 2012;10:2254\u201363.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"832_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/cpdd.167","volume":"4","author":"I Nestorov","year":"2015","unstructured":"Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clin Pharmacol Drug Dev. 2015;4(3):163\u201374.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"6","key":"832_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/jth.13662","volume":"5","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Roberts J, Tortorici M, Veldman A, St Ledger K, Feussner A, et al. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J Thromb Haemost. 2017;5(6):1106\u201314.","journal-title":"J Thromb Haemost."},{"issue":"2","key":"832_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","volume":"119","author":"S Bj\u00f6rkman","year":"2012","unstructured":"Bj\u00f6rkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612\u20138.","journal-title":"Blood."},{"key":"832_CR21","unstructured":"US FDA. Adynovate. Summary basis for regulatory action. 2016. https:\/\/wayback.archiveit.org\/7993\/20170112211013\/http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM535794.pdf. Accessed 01 Nov 2018."},{"key":"832_CR22","unstructured":"US FDA. Adynovate\u00ae prescribing information. 2016. https:\/\/www.fda.gov\/media\/94470\/download. Accessed 01 Nov 2019."},{"issue":"4","key":"832_CR23","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.3390\/pharmaceutics9040047","volume":"9","author":"A McEneny-King","year":"2017","unstructured":"McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of body weight metrics for effective and cost-efficient conventional factor VIII dosing in hemophilia A prophylaxis. Pharmaceutics. 2017;9(4):E47.","journal-title":"Pharmaceutics."},{"issue":"22","key":"832_CR24","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1182\/blood.V128.22.4958.4958","volume":"128","author":"AP Kidwell","year":"2016","unstructured":"Kidwell AP, Bhatt N, Simpson ML, Boggio LN. Dosing factor in pediatric and adult hemophilia patients using ideal body weight versus actual body weight [abstract]. Blood. 2016;128(22):4958.","journal-title":"Blood."},{"issue":"9","key":"832_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3324\/haematol.2013.084038","volume":"98","author":"S Henrard","year":"2013","unstructured":"Henrard S, Speybroeck N, Hermans C. Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients. Haematologica. 2013;98(9):1481\u20136.","journal-title":"Haematologica."},{"issue":"2","key":"832_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/hae.12300","volume":"20","author":"A Graham","year":"2014","unstructured":"Graham A, Jaworski K. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia. 2014;20(2):226\u20139.","journal-title":"Haemophilia."},{"issue":"6","key":"832_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/jth.13682","volume":"15","author":"E Berntorp","year":"2017","unstructured":"Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. J Thromb Haemost. 2017;15(6):1103\u20135.","journal-title":"J Thromb Haemost."},{"issue":"1","key":"832_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/asheducation-2017.1.595","volume":"2017","author":"A Iorio","year":"2017","unstructured":"Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology Am Soc Hematol Educ Program. 2017;2017(1):595\u2013604.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"832_CR29","unstructured":"Lee M, Morfini S, Schulman S, Ingerslev J. The Factor VIII\/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee Communication. The design and analysis of pharmacokinetic studies of coagulation factors. 2001. http:\/\/c.ymcdn.com\/sites\/www.isth.org\/resource\/group\/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e\/official_communications\/fviiipharmaco.pdf. Accessed 19 Feb 2018."},{"issue":"4","key":"832_CR30","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.2196\/resprot.6558","volume":"5","author":"A Iorio","year":"2016","unstructured":"Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, WAPPS-Hemo Co-Investigator Network, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc. 2016;5(4):e239.","journal-title":"JMIR Res Protoc"},{"issue":"4","key":"832_CR31","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.2196\/resprot.6559","volume":"5","author":"A McEneny-King","year":"2016","unstructured":"McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the Web-Accessible Population Pharmacokinetic Service\u2014Hemophilia (WAPPS-Hemo). JMIR Res Protoc. 2016;5(4):e232.","journal-title":"JMIR Res Protoc"},{"issue":"3","key":"832_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","volume":"7","author":"PW Collins","year":"2009","unstructured":"Collins PW, Blanchette VS, Fischer K, Bj\u00f6rkman S, Oh M, Fritsch S, rAHF-PFM Study Group, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413\u201320.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"832_CR33","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s40262-016-0492-2","volume":"56","author":"A Shah","year":"2017","unstructured":"Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, et al. Improved pharmacokinetics with BAY 81-8973 versus antihemophilic factor (recombinant) plasma\/albumin-free method: a randomized pharmacokinetic study in patients with severe hemophilia A. Clin Pharmacokinet. 2017;56(9):1045\u201355.","journal-title":"Clin Pharmacokinet."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00832-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T12:27:24Z","timestamp":1722083244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00832-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00832-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"21 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alexander Solms, Anita Shah, and Dirk Garmann are employees of Bayer. Alfonso Iorio has received project-based funding via research or service agreements with Bayer, Bioverativ, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, and Shire. Maurice J. Ahsman and Peter Vis were compensated by Bayer for analysis of study data. Erik Berntorp has received research funding from Bayer, Bioverativ, Shire, and Sobi; honoraria for lectures and advisory boards from Bayer, CSL Behring, Grifols, LFB, Octapharma, Pfizer, and Shire; and consultancy fees from Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}